Skip to content
  • Career
  • Support
  • Contact Us
Menu
  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Search
Close this search box.
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get a Quote
    • Get Set Up
  • News & Events
    • News
    • Events
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us
  • All posts

A New Study Finds Strong Association Between Adverse Muscle Composition and All-Cause Mortality in NAFLD

  • March 22, 2023

LINKÖPING, Sweden, March 22, 2023 — AMRA researchers together with Linköping University and Virginia Commonwealth University conducted a large, observational study to investigate the associations of all-cause mortality with liver fat, non-alcoholic fatty liver disease (NAFLD), and muscle composition. 

A key assessment in this study was the adverse muscle composition (AMC), which is the combination of low muscle volume z-score with high muscle fat infiltration. Based on previous studies, AMC is prevalent in people with NAFLD and has been linked to increased comorbidity (coronary heart disease and Type 2 diabetes) and poor function in NAFLD, as well as to all-cause mortality within the general population. 

This study analyzed images from the magnetic resonance imaging (MRI) of 40,174 UK Biobank participants to quantify liver fat and muscle composition. In order to detect AMC, the following key measurements were obtained: 

  • fat-free muscle volume (FFMV) z-score
  • muscle fat infiltration (MFI)

This was done using AMRA Medical’s MRI-based technology— a volumetric assessment with the unique capacity to measure both FFMV and MFI.

The study found that AMC was the strongest predictor of all-cause mortality, even when compared to measures of functional performance such as low hand grip strength and slow walking pace. Furthermore, although the combination of FFMV z-score and MFI identified the participants at the highest risk, MFI proved a strong and independent predictor of all-cause mortality by itself and remained significant after adjusting for relevant comorbidities. 

The results of this study have clear and important implications for the early detection and management of NAFLD. Furthermore, the ability to precisely analyze muscle composition has broad applications for assessing treatment in any progressive disease that causes loss of muscle mass and function (i.e., sarcopenia). By considering muscle health in the early stages of liver disease, healthcare professionals can identify high-risk patients and implement preventative care to reduce the risk of all-cause mortality. 

“A combined assessment of both muscle volume and fat infiltration has been shown to effectively stratify the most vulnerable individuals within a wide range of individuals, from the general population to NAFLD, chronic kidney disease, critically ill patients, and patients with pancreatic cancer.”

Read the full publication titled ‘Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD’ at https://doi.org/10.1016/j.jhepr.2022.100663

 

About AMRA Medical

AMRA is a health informatics company at the forefront of medical imaging and precision medicine. The company has developed a game-changing body composition assessment through their whole-body MRI-based technology, which accurately assesses key measurements, such as muscle composition (MFI and FFMV) and body fat distribution (visceral-, subcutaneous, and liver fat). The objective assessment of muscle quality and quantity, along with a unique informatics platform, can give insight into varying muscle phenotypes in different disease progression states, appealing to any group investigating the biological nuances of liver disease or developing the next generation of liver disease therapeutics and interventions. Such research has led to AMRA’s clinical offering which may assist clinicians with patient care decisions.

Learn more about AMRA Medical’s MRI-based clinical services or connect with our team of experts for a detailed discussion at info@amramedical.com.

 

Media Contact AMRA Medical

Marie Börjesson
Senior Director Brand & Marketing
marie.borjesson@amramedical.com
+46 706-281-977

  • All posts
Research Services
Follow us
Linkedin Twitter Facebook

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support
  • Data Privacy Policy
  • Cookie Policy
  • Data Privacy Policy
  • Cookie Policy

Newsletter

    © 2023 AMRA Medical AB

    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}
    AMRA Medical
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    View preferences
    {title} {title} {title}